CN110117582B - 融合蛋白、其编码基因及在生物合成上的应用 - Google Patents

融合蛋白、其编码基因及在生物合成上的应用 Download PDF

Info

Publication number
CN110117582B
CN110117582B CN201910392068.1A CN201910392068A CN110117582B CN 110117582 B CN110117582 B CN 110117582B CN 201910392068 A CN201910392068 A CN 201910392068A CN 110117582 B CN110117582 B CN 110117582B
Authority
CN
China
Prior art keywords
leu
ala
gly
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201910392068.1A
Other languages
English (en)
Other versions
CN110117582A (zh
Inventor
刘春生
李妍芃
尹艳
高伟
姜丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910392068.1A priority Critical patent/CN110117582B/zh
Publication of CN110117582A publication Critical patent/CN110117582A/zh
Application granted granted Critical
Publication of CN110117582B publication Critical patent/CN110117582B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12N9/1037Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/01Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01074Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明涉及一种融合蛋白,所述融合蛋白包含查尔酮合成酶和查尔酮还原酶,查尔酮合成酶和查尔酮还原酶通过一连接子GGGS相连,以及编码本发明所述融合蛋白的基因和包含所述基因的重组工程菌,本发明所述融合蛋白可用于查尔酮和异甘草素的生物合成。

Description

融合蛋白、其编码基因及在生物合成上的应用
技术领域
本发明涉及一种融合蛋白及所述融合蛋白编码基因、包含所述融合蛋白编码基因的表达载体和重组菌,以及所述融合蛋白或重组均在异甘草素合成中的的应用,属于药用成分合成生物学领域。
背景技术
作为一味有几千年历史的古老植物药,甘草(Glycyrrhizae Radix et Rhizoma)是最常用的大宗珍稀濒危药材之一,对多种疾病表现了良好又安全的预防和治疗作用,几乎出现在所有中医处方、成药,和越来越多的保健品甚至食品中。异甘草素是甘草中含量较高的一种查尔酮,也是一种常用天然色素,结构简单,研究发现具有抗炎、抗癌、抗组织胺、抗氧化、抗血小板凝集、抗癌、抗过敏、抗病毒和***样等多种显著活性,其中,抗癌活性较为突出,能够抑制多种癌细胞增殖和诱导它们凋亡。它的糖苷化合物异甘草苷能够抑制肿瘤血管的新生、抗抑郁作用和抗氧化。这些都预示着异甘草素在癌症治疗等方面有更好的开发和应用前景。但甘草中植物中异甘草素含量有限,且由于市场的巨大需求量,早在2009年中国野生甘草蕴藏量已经不足50万t。对野生甘草等掠夺性采挖,不仅造成了甘草大幅减产,也导致甘草种植区环境的破坏和沙漠化,甘草种群被破坏后难以得到恢复。为缓解药源不足,有大量通过化学方法来合成异甘草素的方式,但化学合成方法需要用到大量的有机溶剂,对环保不利,且存在一定的***风险。因此也发展出了组织细胞培养等方法来获得异甘草素,但产量太低,耗时太长。异源生物合成异甘草素成为甘草资源可持续发展的有效策略。异甘草素属于5-氧化查尔酮,其生物合成途径起始于苯丙烷途径,在苯丙氨酸解氨酶(phenylalanine ammo-nialyase,PAL)、肉桂酸4-羟化酶(cinnamate 4-hydroxylase,C4H)和香豆酰-CoA连接酶(4-coumarate:CoA ligase,4CL)的逐步催化下,将苯丙氨酸转化为香豆酰CoA,随后3分子丙二酰辅酶A和1分子香豆酰辅酶A在查耳酮合成酶(chalconesynthase,CHS)和查尔酮还原酶(chalcone reductase,CHR)的作用下生成异甘草素。甘草中异甘草素生物合成途径基因(PAL,C4H,4CL,CHS和CHR)的克隆,为利用发酵工程大量生产活性成分异甘草素提供重要基础。
发明内容
具体地,本发明第一方面涉及一种融合蛋白,所述融合蛋白包含:
(1)查尔酮合成酶(CHS);和
(2)查尔酮还原酶(CHR);
所述查尔酮合成酶和查尔酮还原酶之间通过一连接子连接,所述连接子为GGGS、GSG、GSGGGGS、GSGEAAAK、GSGEAAAKEAAAK或GSGMGSSSN中的任意一种。
本发明的一个具体实施方案中,涉及到一种融合蛋白,该融合蛋白包含SEQ IDNO:8所示氨基酸序列的CHS和SEQ ID NO:10所示氨基酸序列的CHR,所述CHS和CHR之间通过一连接子连接,所述连接子为GGGS、GSG、GSGGGGS、GSGEAAAK、GSGEAAAKEAAAK或GSGMGSSSN中的任意一种,如可以是GGGS。
在本发明的第二方面,本发明还涉及编码本发明所述融合蛋白的多核苷酸序列,所述多核苷酸序列包含:SEQ ID NO:7所述查尔酮合成酶编码基因(CHS)和SEQ ID NO:9所述查尔酮还原酶编码基因(CHR),优选地,所述CHS和CHR之间通过一linker序列连接,如linker序列可以是GGTGGTGGTTCT,更具体地,比如可以是在CHS在3’端(去除SEQ ID NO:7所示终止密码子TGA后)通过linker序列GGTGGTGGTTCT连接到CHR的5’端形成CHS::CHR。
本发明第三方面还涉及重组表达载体,其包含启动子、编码本发明所述融合蛋白的多核苷酸和转录终止子,所述表达载体优选为将启动子、编码本发明所述融合蛋白的多核苷酸、终止子与附加型载体采用酵母同源重组的方法拼接起来,其中附加型载体为酵母表达载体,如选自pESC、pYX212、pYES2.0、pRS425、pRS426和p424;优选地为pESC表达载体,所述pESC表达载体选自pESC-Leu、pESC-His或pESC-Trp。。
一个优选的实施方案中,本发明所述表在载体可以是选自以下中的任意一种:
重组表达载体pYM3,其包含CHS和CHR,所述CHS在3’端(SEQ ID NO:7所示核苷酸序列去除终止密码子TGA后)通过linker序列GGTGGTGGTTCT连接到CHR的5’端形成CHS::CHR,所述CHS::CHR***到表达载体pESC-Leu的启动子GAL10下游;
重组表达载体pYM2,其包括编码SEQ ID NO:6所示氨基酸序列的香豆酰-CoA连接酶编码基因(4CL)、CHS和CHR,所述CHS在3’端(SEQ ID NO:7所示核苷酸序列去除终止密码子TGA后)通过linker序列GGTGGTGGTTCT连接到CHR的5’端形成CHS::CHR,所述4CL***酵母表达载体pESC-Leu的启动子GAL1下游,所述CHS::CHR***到表达载体pESC-Leu的启动子GAL10下游;所述的编码SEQ ID NO:6所示氨基酸序列的香豆酰-CoA连接酶编码基因可以是如SEQ ID NO:5所示核苷酸序列。
本发明的第四方面,还涉及到一种重组酵母工程菌,所述重组酵母工程菌,包含编码本发明所述融合蛋白的多核苷酸序列、或本发明第四方面所述的重组表达载体。
在本发明的第五方面,涉及到一种优选的重组酵母工程菌,所述的优选的重组酵母工程菌,为在本发明第四方面酵母工程菌中,进一步包含表达载体pYM1,所述表达载体pYM1包含编码SEQ ID NO:2所示氨基酸序列的苯丙氨酸解氨酶编码基因(PAL)和编码SEQID NO:4所示氨基酸序列的肉桂酸4-羟化酶编码基因(C4H),所述PAL***到表达载体pESC-His的启动子GAL1的下游,所述C4H***到表达载体pESC-His的启动子GAL10的下游。
具体地,编码SEQ ID NO:2所示氨基酸序列的苯丙氨酸解氨酶编码基因(PAL)可以是如SEQ ID NO:1所示核苷酸序列;编码SEQ ID NO:4所示氨基酸序列的肉桂酸4-羟化酶编码基因(C4H)可以是如SEQ ID NO:3所示核苷酸序列。
本发明的第六方面,涉及到一种构建本发明所述重组酵母工程菌的方法,所述酵母工程菌的构建方法为:
将重组表达载体pYM3转入到酵母工程菌WAT11中,得到菌株WM4;或
将重组表达载体pYM2转入到酵母工程菌WAT11中,得到菌株WM3;或
将重组表达载体pYM1和pYM2转入到酵母工程菌WAT11中,得菌株WM2-1;或
将重组表达载体pYM1、pYM2和pYM3转入到酵母工程菌WAT11中,得菌株WM2-2。
本发明的第七方面,涉及本发明所述融合蛋白、或编码本发明所述融合蛋白的多核苷酸、包含本发明所述多核苷酸的重组表达载体、或本发明所述的重组酵母工程菌在生产查尔酮或异甘草素中的应用,半乳糖诱导发酵所得菌株后,用乙酸乙酯提取发酵液,经LC-MS检测,可检测到异甘草素。
本发明还涉及上文所述PAL,C4H,4CL,CHS或CHR基因在酿酒酵母发酵中的应用,具体可以应用于发酵工程合成异甘草素及其他黄酮类生物合成中间体的制备。进一步,所述的其他黄酮类生物合成中间体为肉桂酸,对香豆酸,对香豆酰辅酶A和柚皮素查尔酮。
利用本发明可以通过生物合成技术来生成异甘草素及黄酮类生物合成中间体肉桂酸,对香豆酸,对香豆酰辅酶A和柚皮素查尔酮,具有很好的应用前景。
本发明还提供了本发明所述苯丙氨酸解氨酶、肉桂酸4-羟化酶、香豆酰-CoA连接酶、查耳酮合成酶和查尔酮还原酶或编码本发明所述苯丙氨酸解氨酶、肉桂酸4-羟化酶、香豆酰-CoA连接酶、查耳酮合成酶和查尔酮还原酶基因,在含有黄酮类化学成分的植物育种中的运用。运用本发明所述苯丙氨酸解氨酶、肉桂酸4-羟化酶、香豆酰-CoA连接酶、查耳酮合成酶和查尔酮还原酶、或其编码基因,通过将其运用到植物细胞中,可改善植物体内黄酮的含量。
附图说明
图1为不同基因编码蛋白催化产物分析图。EIC(extracted ion chromatogram)即提取离子流图,图中m/z 164、147、163、271和255分别为苯丙氨酸、肉桂酸、对香豆酸、柚皮素查尔酮和异甘草素[M-H]-的核质比。
图2为重组酵母菌WM1、WM2-1及WM2-2发酵产物分析图。图2A中m/z 163和255分别为对香豆酸和异甘草素[M-H]-的核质比。
图3为重组酵母菌WM3、WM4及WM5发酵产物分析图。图中m/z 163和255分别为对香豆酸和异甘草素[M-H]-的核质比。
具体实施方式
以下通过优选实施例并结合附图具体说明本发明的各个方面和特征,本领域的技术人员应该理解,这些实施例只是用于说明,而不是限制本发明的范围。在不背离权利要求书范围的条件下,本领域的技术人员可以对本发明的各个方面进行各种修改和改进,这些修改和改进也属于本发明的保护范围。例如,将实施例中所实用表达载体和宿主菌替换为本领域中常用的其它表达载体和宿主菌,是本领域的普通技术人员所能够理解并实现的。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1乌拉尔甘草中异甘草素生物合成途径酶基因的克隆
1.引物设计
根据乌拉尔甘草转录组数据注释筛选得到基因全长序列片段,设计上游和下游克隆引物,引物序列如下:
Figure BDA0002056843640000031
2.PCR扩增
利用QuantScript RT Kit(天根生化科技有限公司,北京,中国)将乌拉尔甘草RNA反转录成cDNA。
以cDNA为模板,进行PCR扩增。
扩增体系为:2×KAPA HiFi Hotstart ReadyMix(Kapa Biosystems,Wilmington,USA)25μL,引物P1和P2各1.5μL,模板2μL,双蒸水补足50μL。反应条件:98℃预变性3min,98℃20s,62℃退火15s,72℃延伸1.5min,35个循环后72℃延伸5min,4℃保存。
测序结果表明,PCR扩增产物的序列分别如SEQ ID No.1、3、5、7和9所示,将序列1、3、5、7和9所示的基因分别命名为PAL,C4H,4CL,CHS和CHR,其编码的蛋白分别命名为PAL,C4H,4CL,CHS和CHR,对应蛋白的氨基酸序列分别为SEQ ID No.2、4、6、8和10所示。
在以下的实施例中,基因PAL,C4H,4CL,CHS和CHR和蛋白PAL,C4H,4CL,CHS和CHR,都是与上对应的核酸或氨基酸序列相同。
实施例2 PAL,CHS和CHR基因的原核表达及体外酶促反应
1、原核表达
PAL,CHS和CHR分别利用EasyGeno Assembly Cloning kit(天根生化科技有限公司,北京,中国)***pET-32a(+)的KpnI和XhoI之间,并转入E.coli BL21(DE3)中。转化子用含100mg/mL氨苄青霉素的LB平板筛选并挑取单克隆测序验证。重组表达细胞在200mL含100mg/mL氨苄青霉素的LB培养基中,37℃震荡培养至OD600=0.6-1.0,用0.2mM的IPTG在16℃诱导10h。5000rpm,4℃离心收集菌体。3mL PBS buffer(pH 8.0)重悬菌体,冰浴超声破碎细菌,离心收集上清。重组蛋白用(康为世纪生物科技有限公司,北京,中国)纯化,用Bradford方法检测浓度。
1.体外酶促反应
1mL体外酶促反应体系各自包括:
重组蛋白PAL约50ng/μL(10mM PBS,pH=8.0),二硫苏糖醇(DTT)1mM,底物苯丙氨酸1mM;
重组蛋白CHS约50ng/μL(10mM PBS,pH=8.0),DTT 1mM,底物1mM(为摩尔质量比为1:3的香豆酰辅酶A和丙二酰辅酶A);
重组蛋白CHS和CHR约50ng/μL(10mM PBS,pH=8.0),DTT 1mM,底物1mM(为摩尔质量比为1:3的香豆酰辅酶A和丙二酰辅酶A);
重组蛋白CHS和CHR约50ng/μL(10mM PBS,pH=8.0),DTT 1mM,底物1mM(为摩尔质量比为1:3的香豆酰辅酶A和丙二酰辅酶A),以及,1mM的NADPH;
各自体系均在30℃孵育12h,加入200μL甲醇终止反应。催化产物12000g离心,上清过0.22μm PTFE滤膜,用HPLC-MS检测。结果如图1A和图1D。与空载对照相比,以苯丙氨酸为底物的PAL1重组蛋白体外酶促体系中产生肉桂酸(图1A),因此认定PAL1具有催化苯丙氨酸生成肉桂酸的活性。
在以摩尔质量比为1:3的香豆酰辅酶A和丙二酰辅酶A为底物的体外酶促体系中,只加入CHS进行孵育时会产生柚皮素查尔酮;同时加入等量CHS、CHR重组蛋白以及NADPH时,除了柚皮素查尔酮外还能检测到异甘草素的产生(图1D);确定CHS、CHR的查耳酮合成酶和查尔酮还原酶活性。
然而,同时加入等量CHS、CHR重组蛋白,但底物中不加入NADPH时,未能检测到异甘草素的产生。
实施例3 C4H和4CL基因的酵母表达及表征
酵母表达载体构建,利用EasyGeno Assembly Cloning kit(天根生化科技有限公司,北京,中国),将C4H或CHS分别***酵母表达载体pESC-His(安捷伦科技有限公司,圣克拉拉市,美国)(或者也可以分别***pESC-Leu(安捷伦科技有限公司,圣克拉拉市,美国))的SpeI和NotI位点之间,4CL***已连接了CHS的重组载体的NheI和BamHI位点之间。重组质粒利用酵母转化试剂盒(Zymo Research Corporation,Irvine,USA)转入宿主菌WAT11,转化子在相应的缺陷培养基(SC-His或-Leu,2%葡萄糖和2%琼脂)上30℃筛选培养4天。阳性克隆于对应的液体缺陷培养基(2%葡萄糖)中,30℃震荡至OD600约0.8。用2%的半乳糖替换葡萄糖的诱导培养基,30℃,220rpm诱导表达6h后,加入20μM肉桂酸或对香豆酸继续培养12h。培养液用等体积乙酸乙酯提取三次,提取物挥干溶剂后,用甲醇复溶,过0.22μm PTFE滤膜,HPLC-MS负离子模式下检测产物。结果如图1B和图1C。以肉桂酸饲喂包含C4H的重组酵母并用半乳糖诱导表达后,能在培养液中检测到对香豆酸(图1B),说明C4H能催化肉桂酸生成对香豆酸。因为4CL催化产物不稳定,将4CL与CHS利用双元表达载体pESC-Leu在WAT11中共表达,用对香豆酸进行饲喂,在培养液提取物中也能检测到柚皮素查尔酮(图1C),说明4CL能利用酵母内源的辅酶A结合对香豆酸生成香豆酰辅酶A,为CHS合成查尔酮提供底物。
实施例4产异甘草素的酵母工程菌的构建
利用EasyGeno Assembly Cloning kit(天根生化科技有限公司,北京,中国)分别:
(1)将基因PAL***双元酵母表达载体pESC-His的启动子GAL1下游,基因C4H***双元酵母表达载体pESC-His的启动子GAL10下游,得到质粒YM1(pHIS-GAL1PAL-GAL10C4H);
(2)将基因4CL***双元酵母表达载体pESC-Leu的启动子GAL1下游,融合基因CHS::CHR***双元酵母表达载体pESC-Leu的启动子GAL10下游(基因CHS::CHR为将CHS去除终止密码子TGA后3’端通过linker序列GGTGGTGGTTCT连接CHR 5’端形成的融合基因(SEQID NO:21)),得到质粒pYM2(pLEU-GAL14CL-GAL10CHS::CHR);
(3)将融合基因CHS::CHR***双元酵母表达载体pESC-TrpGAL10启动子的下游,得到质粒pYM3(pTRP-GAL10CHS::CHR)。
(4)将基因CHS***双元酵母表达载体pESC-His的启动子GAL1下游,基因CHR***双元酵母表达载体pESC-His的启动子GAL10下游,得到质粒pYM4(pHIS-GAL1CHS-GAL10CHR)
利用酵母转化试剂盒(Zymo Research Corporation,Irvine,USA)分别将:
(1)重组表达载体pYM1转入到酵母工程菌WAT11中,得到转化子1;
(2)重组表达载体pYM1和pYM2转入到酵母工程菌WAT11中,得到转化子2;
(3)重组表达载体pYM1、pYM2和pYM3转入到酵母工程菌WAT11中,得到转化子3;
(4)重组表达载体pYM2转入到酵母工程菌WAT11中,得到转化子4;
(5)重组表达载体pYM3转入到酵母工程菌WAT11中,得到转化子5;
(6)重组表达载体pYM4转入到酵母工程菌WAT11中,得到转化子6;
各转化子根据载体标签在相应的缺陷培养基(SC-His(转化子1、转化子6)、SC-His-Lue(转化子2)、SC-His-Lue-Trp(转化子3)、SC-Leu(转化子4)或SC-Trp(转化子5),2%葡萄糖和2%琼脂)上30℃筛选培养4天。获得的阳性克隆重组酵母菌株分别命名为WM1(包含pYM1)、WM2-1(包含pYM1和pYM2)、WM2-2(包含pYM1、pYM2和pYM3)、WM3(包含pYM2)、WM4(包含pYM3)和WM5(包含pYM4)。
重组酵母分别于对应液体缺陷培养基(SC-His(WM1),SC-His-Lue(WM2-1)或SC-His-Lue-Trp(WM2-2),2%葡萄糖)中,30℃震荡至OD600约0.8。用2%的半乳糖替换葡萄糖的诱导培养基,30℃,220rpm诱导表达12-48h。培养液用等体积乙酸乙酯提取三次,提取物挥干溶剂后,用甲醇复溶,过0.22μm PTFE滤膜,HPLC-MS负离子模式下检测产物。结果如图2。重组酵母WM1在半乳糖诱导发酵下能产生对香豆酸(图2A),培养36h左右检测对香豆酸产量在7.59umol/L(图2B)。向WM1中转入pYM2时,在发酵液里能检测到少量的异甘草素(图2,WM2-1)。而过表达CHS::CHR能使WM2-2的异甘草素产量与WM2-1相比上升18.2倍(图2B)。
重组酵母菌WM3、WM4和WM5依次对应液体缺陷培养基(SC-Leu、SC-Trp或SC-His,2%葡萄糖)中,30℃震荡至OD600约0.8。用2%的半乳糖替换葡萄糖的诱导培养基,30℃,220rpm诱导表达6h后,加入20μM对香豆酸继续培养WM3,加入20μM香豆酰辅酶A继续培养WM4和WM5。12h后将培养液用等体积乙酸乙酯提取三次,提取物挥干溶剂后,用甲醇复溶,过0.22μm PTFE滤膜,HPLC-MS负离子模式下检测产物。结果表明,用对香豆酸(WM3)或香豆酰辅酶A(WM4)进行饲喂,在培养液提取物中也能检测到异甘草素,而用香豆酰辅酶A饲喂WM5不能获得异甘草素(图3)。
上述说明并非对本发明的限制,本发明也并不限于上述举例。本技术领域的普通技术人员在本发明的实质范围内,作出的变化、改型、添加或替换,也应属于本发明的保护范围,本发明的保护范围以权利要求书为准。
SEQUENCE LISTING
<110> 刘, 春生
<120> 融合蛋白、其编码基因及在生物合成上的应用
<130> 背景技术中
<160> 21
<170> PatentIn version 3.5
<210> 1
<211> 2352
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 1
atgccccatt ctctctccct cttcccttca ggaaatcctt tgattccccc cacaaccaaa 60
gatttcctct cctctcatca actactacaa ctattattat tattactact actactctct 120
cctctccctt ctctatctct tcagcattcc ttaaatacat ttttactctc ttttcgtcgt 180
gacaattcat caaacatgga cgctactaca gccaatggcc atgtcgtcga cggtgtcaat 240
agtttttgct tgaagagcgg tagtggtggt ggtgatccat tgaactgggg tgcggcggcg 300
gagtcgatga aggggagtca cttggacgag gtgaaacgga tggtggcgga gtaccggaag 360
ccggtggtgc ggctcggcgg cgagagcctc acgattgctc aggtggccgg catcgcctca 420
cacgacaccg gcgtacgcgt ggagctgtcg gagtcggcga gggcaggggt taaggcaagc 480
agtgactggg tgatggacag catgaataat ggcaccgaca gctacggtgt caccaccggt 540
ttcggtgcta cctcccaccg tagaaccaaa cagggcggtg ccttgcagaa ggagctaatt 600
aggtttttga atgctggaat atttggcaat ggtacggagt caaattgcac cctaccacac 660
acagcaacaa gggcagcaat gctagtgaga atcaacaccc ttcttcaagg ctactctggc 720
attagatttg aaatcttaga agccatgaca aagttcctaa acagcaacat caccccatgc 780
ctaccactaa ggggaacaat tacagcatct ggtgaccttg tccctctttc ttacattgcc 840
ggtttgttaa cgggcagacc caattccaaa gctgtgggac ccactggaga gattctcaat 900
gccaaggaag catttcaatt ggccaaaatt ggttcagagt tctttgaatt gcaacccaaa 960
gaaggccttg cacttgttaa tggcactgcc gttggttctg gtttggcttc aatcgttctg 1020
tttgaagcaa acattctagc tgttttgtct gaagttatat cagcaatttt cgctgaagtt 1080
atgcaaggga aacctgaatt cactgactat ttgacacata aactgaaaca ccatcctggg 1140
caaatcgaag ctgcagctat tatggagcat gttttggatg gaagctctta tgttaaagca 1200
gctaagaagt tgcatgaggt tgacccttta caaaagccta aacaggatcg ctatgcactt 1260
aggacttcac cacaatggct tggtccttta attgaagtga taaggttctc aactaagtca 1320
attgagagag agattaactc ggtcaatgac aaccctttga ttgatgtgtc aaggaacaag 1380
gctttacatg gtggtaactt tcagggaaca cctattgggg tctcaatgga taacacacgt 1440
ttggcacttg cttcaattgg taaactcatg tttgctcaat tctctgagct tgttaatgat 1500
ttttacaaca atgggttgcc ttcgaatctc tctggtggta gaaacccaag cttggattat 1560
ggtttcaagg gagctgaaat tgctatggct tcttattgct ctgagctaca ataccttgca 1620
aacccggtta caagccatgt acaaagtgct gaacaacaca accaggatgt gaactcgttg 1680
ggtttgattt cttctaggaa aacaaacgag gccattgaga tccttaagct catgtcttcc 1740
acgttcttga ttgcactctg ccaagctatt gacttgaggc acttggagga gaacctgagg 1800
aacaccgtca agaacaccgt gagccaagtt gccaagagga cactcaccac aggtgtcaat 1860
ggagaactcc acccttctag attctgtgag aaagacttgc tcaaggttgt tgatagggag 1920
tatgtttttg cctacattga cgacccttgc agtgccacgt acccattgat gcaaaagctg 1980
aggcaagtgc ttgtggatca tgcacttgta aatggagaga gcgagaagag cttgaacaca 2040
tcgatcttcc aaaagattgc aacttttgag gatgagttga aggccctttt gccaaaagag 2100
gtggaaggtg cgagggttgc atatgagaat gggcaatgtg caatcccgaa caagatcaag 2160
gaatgtaggt catacccgtt gtacaagttt gtgagggaag agttggggac agggttgtta 2220
acaggggaga aggtgatttc accgggtgag gagtgtgaca aactgttcat agcaatgtgc 2280
cagggtaaga ttattgatcc ccttttggaa tgccttgggg agtggaatgg tgcgcctctt 2340
ccaatttgtt aa 2352
<210> 2
<211> 783
<212> PRT
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 2
Met Pro His Ser Leu Ser Leu Phe Pro Ser Gly Asn Pro Leu Ile Pro
1 5 10 15
Pro Thr Thr Lys Asp Phe Leu Ser Ser His Gln Leu Leu Gln Leu Leu
20 25 30
Leu Leu Leu Leu Leu Leu Leu Ser Pro Leu Pro Ser Leu Ser Leu Gln
35 40 45
His Ser Leu Asn Thr Phe Leu Leu Ser Phe Arg Arg Asp Asn Ser Ser
50 55 60
Asn Met Asp Ala Thr Thr Ala Asn Gly His Val Val Asp Gly Val Asn
65 70 75 80
Ser Phe Cys Leu Lys Ser Gly Ser Gly Gly Gly Asp Pro Leu Asn Trp
85 90 95
Gly Ala Ala Ala Glu Ser Met Lys Gly Ser His Leu Asp Glu Val Lys
100 105 110
Arg Met Val Ala Glu Tyr Arg Lys Pro Val Val Arg Leu Gly Gly Glu
115 120 125
Ser Leu Thr Ile Ala Gln Val Ala Gly Ile Ala Ser His Asp Thr Gly
130 135 140
Val Arg Val Glu Leu Ser Glu Ser Ala Arg Ala Gly Val Lys Ala Ser
145 150 155 160
Ser Asp Trp Val Met Asp Ser Met Asn Asn Gly Thr Asp Ser Tyr Gly
165 170 175
Val Thr Thr Gly Phe Gly Ala Thr Ser His Arg Arg Thr Lys Gln Gly
180 185 190
Gly Ala Leu Gln Lys Glu Leu Ile Arg Phe Leu Asn Ala Gly Ile Phe
195 200 205
Gly Asn Gly Thr Glu Ser Asn Cys Thr Leu Pro His Thr Ala Thr Arg
210 215 220
Ala Ala Met Leu Val Arg Ile Asn Thr Leu Leu Gln Gly Tyr Ser Gly
225 230 235 240
Ile Arg Phe Glu Ile Leu Glu Ala Met Thr Lys Phe Leu Asn Ser Asn
245 250 255
Ile Thr Pro Cys Leu Pro Leu Arg Gly Thr Ile Thr Ala Ser Gly Asp
260 265 270
Leu Val Pro Leu Ser Tyr Ile Ala Gly Leu Leu Thr Gly Arg Pro Asn
275 280 285
Ser Lys Ala Val Gly Pro Thr Gly Glu Ile Leu Asn Ala Lys Glu Ala
290 295 300
Phe Gln Leu Ala Lys Ile Gly Ser Glu Phe Phe Glu Leu Gln Pro Lys
305 310 315 320
Glu Gly Leu Ala Leu Val Asn Gly Thr Ala Val Gly Ser Gly Leu Ala
325 330 335
Ser Ile Val Leu Phe Glu Ala Asn Ile Leu Ala Val Leu Ser Glu Val
340 345 350
Ile Ser Ala Ile Phe Ala Glu Val Met Gln Gly Lys Pro Glu Phe Thr
355 360 365
Asp Tyr Leu Thr His Lys Leu Lys His His Pro Gly Gln Ile Glu Ala
370 375 380
Ala Ala Ile Met Glu His Val Leu Asp Gly Ser Ser Tyr Val Lys Ala
385 390 395 400
Ala Lys Lys Leu His Glu Val Asp Pro Leu Gln Lys Pro Lys Gln Asp
405 410 415
Arg Tyr Ala Leu Arg Thr Ser Pro Gln Trp Leu Gly Pro Leu Ile Glu
420 425 430
Val Ile Arg Phe Ser Thr Lys Ser Ile Glu Arg Glu Ile Asn Ser Val
435 440 445
Asn Asp Asn Pro Leu Ile Asp Val Ser Arg Asn Lys Ala Leu His Gly
450 455 460
Gly Asn Phe Gln Gly Thr Pro Ile Gly Val Ser Met Asp Asn Thr Arg
465 470 475 480
Leu Ala Leu Ala Ser Ile Gly Lys Leu Met Phe Ala Gln Phe Ser Glu
485 490 495
Leu Val Asn Asp Phe Tyr Asn Asn Gly Leu Pro Ser Asn Leu Ser Gly
500 505 510
Gly Arg Asn Pro Ser Leu Asp Tyr Gly Phe Lys Gly Ala Glu Ile Ala
515 520 525
Met Ala Ser Tyr Cys Ser Glu Leu Gln Tyr Leu Ala Asn Pro Val Thr
530 535 540
Ser His Val Gln Ser Ala Glu Gln His Asn Gln Asp Val Asn Ser Leu
545 550 555 560
Gly Leu Ile Ser Ser Arg Lys Thr Asn Glu Ala Ile Glu Ile Leu Lys
565 570 575
Leu Met Ser Ser Thr Phe Leu Ile Ala Leu Cys Gln Ala Ile Asp Leu
580 585 590
Arg His Leu Glu Glu Asn Leu Arg Asn Thr Val Lys Asn Thr Val Ser
595 600 605
Gln Val Ala Lys Arg Thr Leu Thr Thr Gly Val Asn Gly Glu Leu His
610 615 620
Pro Ser Arg Phe Cys Glu Lys Asp Leu Leu Lys Val Val Asp Arg Glu
625 630 635 640
Tyr Val Phe Ala Tyr Ile Asp Asp Pro Cys Ser Ala Thr Tyr Pro Leu
645 650 655
Met Gln Lys Leu Arg Gln Val Leu Val Asp His Ala Leu Val Asn Gly
660 665 670
Glu Ser Glu Lys Ser Leu Asn Thr Ser Ile Phe Gln Lys Ile Ala Thr
675 680 685
Phe Glu Asp Glu Leu Lys Ala Leu Leu Pro Lys Glu Val Glu Gly Ala
690 695 700
Arg Val Ala Tyr Glu Asn Gly Gln Cys Ala Ile Pro Asn Lys Ile Lys
705 710 715 720
Glu Cys Arg Ser Tyr Pro Leu Tyr Lys Phe Val Arg Glu Glu Leu Gly
725 730 735
Thr Gly Leu Leu Thr Gly Glu Lys Val Ile Ser Pro Gly Glu Glu Cys
740 745 750
Asp Lys Leu Phe Ile Ala Met Cys Gln Gly Lys Ile Ile Asp Pro Leu
755 760 765
Leu Glu Cys Leu Gly Glu Trp Asn Gly Ala Pro Leu Pro Ile Cys
770 775 780
<210> 3
<211> 1518
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 3
atggatctcc tccttctgga gaagacccta ttgggtctct tcatcgccgc cataaccgcc 60
attgcaatct caaagctccg aggccggcga ttcaagctcc caccgggacc aatcccggta 120
ccaatcttcg gtaactggct ccaagtcggc gacgacctca accaccgcaa cctcaccgac 180
ctagcgaaac gcttcggcga catcttcctc ctccgaatgg gacagcgaaa cctcgtcgtc 240
gtttcatcgc cggagctagc caaggaggtc ctccacacac agggcgtgga attcggatcc 300
cgaacacgaa acgtcgtatt cgacatcttc accggaaagg gacaagacat ggtgttcacc 360
gtctacggcg aacactggcg gaagatgagg aggatcatga cggtgccctt tttcaccaac 420
aaggttgttc agcagtaccg gttcgggtgg gaatctgagg ctgctagtgt cgtcgatgat 480
gttcggcgta accccgatgc agccgccggc gggattgtac tccgccggag acttcagctc 540
atgatgtata acaatatgta tcggattatg tttgatagga ggtttgagag tgaggaggat 600
cctctgttta tgaagctgaa ggctctgaat ggggagagga gtcgtttggc acagagtttt 660
gagtataact atggggattt cattcctatt ttgagaccct tcttgaaagg ttacttgacg 720
atttgtaagg aggttaagga gaggaggttg aagctcttca aggactattt cgttgatgag 780
aggatgaagc ttgaaagcac aaagagcacc agcaacgaag gacttaaatg cgctattgat 840
cacattttgg acgctcagaa gaagggtgag atcaacgaag acaacgtcct ttacattgtt 900
gagaacatca acgttgctgc aattgaaaca actctatggt caattgaatg gggaattgct 960
gagcttgtga accacccaga gatccaaaag aaagtgaggg atgagattga cagagttctt 1020
ggaccaggac accaagtgac tgagccagat atgcagaagc taccttacct tcaggcagtg 1080
atcaaggaga cactccggct ccgaatggcg atcccgctcc tcgtcccaca catgaacctc 1140
cacgacgcaa agctcggtgg gtacgacatt ccggcggaga gcaagatatt ggtgaatgca 1200
tggtggcttg caaacaaccc tgctaattgg aaaaggccag aggagtttag gccagagagg 1260
ttcttagagg aagagtcaca tgttgaggct aatgggaatg actttaggta ccttccattt 1320
ggtgttggta gaaggagttg ccctggaatc attcttgctt tgcctatcct tggtattact 1380
ttgggacgtt tggttcaaaa ttttgagcta ttgcctcctc ctggacagtc caaacttgac 1440
actgctgaga aaggagggca attcagtttg cacatactca aacactcaac cattgttgcc 1500
aagccaagat cattttag 1518
<210> 4
<211> 505
<212> PRT
<213> Artificial Sequence
<220>
<223> aritficial sequence
<400> 4
Met Asp Leu Leu Leu Leu Glu Lys Thr Leu Leu Gly Leu Phe Ile Ala
1 5 10 15
Ala Ile Thr Ala Ile Ala Ile Ser Lys Leu Arg Gly Arg Arg Phe Lys
20 25 30
Leu Pro Pro Gly Pro Ile Pro Val Pro Ile Phe Gly Asn Trp Leu Gln
35 40 45
Val Gly Asp Asp Leu Asn His Arg Asn Leu Thr Asp Leu Ala Lys Arg
50 55 60
Phe Gly Asp Ile Phe Leu Leu Arg Met Gly Gln Arg Asn Leu Val Val
65 70 75 80
Val Ser Ser Pro Glu Leu Ala Lys Glu Val Leu His Thr Gln Gly Val
85 90 95
Glu Phe Gly Ser Arg Thr Arg Asn Val Val Phe Asp Ile Phe Thr Gly
100 105 110
Lys Gly Gln Asp Met Val Phe Thr Val Tyr Gly Glu His Trp Arg Lys
115 120 125
Met Arg Arg Ile Met Thr Val Pro Phe Phe Thr Asn Lys Val Val Gln
130 135 140
Gln Tyr Arg Phe Gly Trp Glu Ser Glu Ala Ala Ser Val Val Asp Asp
145 150 155 160
Val Arg Arg Asn Pro Asp Ala Ala Ala Gly Gly Ile Val Leu Arg Arg
165 170 175
Arg Leu Gln Leu Met Met Tyr Asn Asn Met Tyr Arg Ile Met Phe Asp
180 185 190
Arg Arg Phe Glu Ser Glu Glu Asp Pro Leu Phe Met Lys Leu Lys Ala
195 200 205
Leu Asn Gly Glu Arg Ser Arg Leu Ala Gln Ser Phe Glu Tyr Asn Tyr
210 215 220
Gly Asp Phe Ile Pro Ile Leu Arg Pro Phe Leu Lys Gly Tyr Leu Thr
225 230 235 240
Ile Cys Lys Glu Val Lys Glu Arg Arg Leu Lys Leu Phe Lys Asp Tyr
245 250 255
Phe Val Asp Glu Arg Met Lys Leu Glu Ser Thr Lys Ser Thr Ser Asn
260 265 270
Glu Gly Leu Lys Cys Ala Ile Asp His Ile Leu Asp Ala Gln Lys Lys
275 280 285
Gly Glu Ile Asn Glu Asp Asn Val Leu Tyr Ile Val Glu Asn Ile Asn
290 295 300
Val Ala Ala Ile Glu Thr Thr Leu Trp Ser Ile Glu Trp Gly Ile Ala
305 310 315 320
Glu Leu Val Asn His Pro Glu Ile Gln Lys Lys Val Arg Asp Glu Ile
325 330 335
Asp Arg Val Leu Gly Pro Gly His Gln Val Thr Glu Pro Asp Met Gln
340 345 350
Lys Leu Pro Tyr Leu Gln Ala Val Ile Lys Glu Thr Leu Arg Leu Arg
355 360 365
Met Ala Ile Pro Leu Leu Val Pro His Met Asn Leu His Asp Ala Lys
370 375 380
Leu Gly Gly Tyr Asp Ile Pro Ala Glu Ser Lys Ile Leu Val Asn Ala
385 390 395 400
Trp Trp Leu Ala Asn Asn Pro Ala Asn Trp Lys Arg Pro Glu Glu Phe
405 410 415
Arg Pro Glu Arg Phe Leu Glu Glu Glu Ser His Val Glu Ala Asn Gly
420 425 430
Asn Asp Phe Arg Tyr Leu Pro Phe Gly Val Gly Arg Arg Ser Cys Pro
435 440 445
Gly Ile Ile Leu Ala Leu Pro Ile Leu Gly Ile Thr Leu Gly Arg Leu
450 455 460
Val Gln Asn Phe Glu Leu Leu Pro Pro Pro Gly Gln Ser Lys Leu Asp
465 470 475 480
Thr Ala Glu Lys Gly Gly Gln Phe Ser Leu His Ile Leu Lys His Ser
485 490 495
Thr Ile Val Ala Lys Pro Arg Ser Phe
500 505
<210> 5
<211> 1653
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 5
atggccattc agaacgagat gaagcagcag caacaacaga tcaaagaaga gttcatattc 60
aagtcgaagc ttcccgatat ccacattccc aaacacctcc ctctgcattc ctactgcttc 120
cagaatcttc cagagttcgg ttcacgtccc tgtctcatca acgccccaac gggtgaaata 180
ttcacctact ccgacgtgga actcgccgca cggagagtcg catcggggct aaaaaaacta 240
ggcatccaac acggcgatgt aatcatggtc ctcctcccaa attgccctga attcgttttc 300
tccttcctcg gcgcttcctt ttgcggcgca atcaccaccg ccgcgaaccc gttcttcacc 360
gccgcggaaa ttgccaaaca ggccaaagcc tcccatggga aggtgatcgt aacacaggct 420
tgttactacg agaaggtgaa ggacttgggt gtgaccaatc tcgtgttcgt ggattctccc 480
cctgaggggc acatgcattt cagcgagttg atggctgatg atgatgacgt catcaccggt 540
gatgaaatta agatccaccc tgatgacgtg gtggctttgc cttattcttc cgggacgacg 600
ggtctcccca aaggggtgat gctgacacac aaggggttgg taacgagcat agcacagcag 660
gtggatgggg agaacccaaa cctttactac cacagcgagg atgtgatcct ctgtgtgctt 720
cccctgtttc acatatactc cctcaactct gttctcctct gtgggttaag ggccaaagcc 780
tccatcttgt tgatgcccaa gttcgacatt catgctttct tgggtctggt tcacaggcac 840
agggtcacca ttgcaccact tgtgcccccc attgttctcg ccattgccaa gtcacctgat 900
cttgataaat atgacctctc atccattagg gtcctcaaat ctggaggggc tccccttggt 960
aaagaacttg aagacactgt cagggccaaa ttcccccaag ccaaacttgg acagggatat 1020
gggatgacgg aggcaggtcc agtgttgaca atgtgcttat catttgcaaa agtgccaata 1080
gatgtaaaac caggtgcatg tggaaccgtc gtcaggaatg cggagatgaa gattgtggat 1140
cctgaaaccg atacttcttt gcctcgaaat caacccggtg aaatctgtat tagaggcgac 1200
caaatcatga aaggttatct gaacgacccg gaagctacag agagaacaat agacaaagaa 1260
ggttggttgc atacgggtga cattgggtac attgacaatg atgatgagtt gttcatcgtt 1320
gataggctga aggaattgat taaatacaaa gggtttcaag tggctccagc tgaactcgaa 1380
gcccttattc tctcacaccc taagatctcc gatgttgctg tggtcccaat gaaggatgaa 1440
gcagctggtg aggtcccagt tgcatttgtg gtgagagcaa atggtcatat cgacacaact 1500
gaggatgaaa ttaagcaatt cgtctccaaa caggtggtgt tttacaaaag aataaacaga 1560
gtattcttca ttgatgccat tcccaagtca ccctcaggca aaatcttacg aaaggaccta 1620
agggctaagc ttgcagcggg tcttccaaat tga 1653
<210> 6
<211> 550
<212> PRT
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 6
Met Ala Ile Gln Asn Glu Met Lys Gln Gln Gln Gln Gln Ile Lys Glu
1 5 10 15
Glu Phe Ile Phe Lys Ser Lys Leu Pro Asp Ile His Ile Pro Lys His
20 25 30
Leu Pro Leu His Ser Tyr Cys Phe Gln Asn Leu Pro Glu Phe Gly Ser
35 40 45
Arg Pro Cys Leu Ile Asn Ala Pro Thr Gly Glu Ile Phe Thr Tyr Ser
50 55 60
Asp Val Glu Leu Ala Ala Arg Arg Val Ala Ser Gly Leu Lys Lys Leu
65 70 75 80
Gly Ile Gln His Gly Asp Val Ile Met Val Leu Leu Pro Asn Cys Pro
85 90 95
Glu Phe Val Phe Ser Phe Leu Gly Ala Ser Phe Cys Gly Ala Ile Thr
100 105 110
Thr Ala Ala Asn Pro Phe Phe Thr Ala Ala Glu Ile Ala Lys Gln Ala
115 120 125
Lys Ala Ser His Gly Lys Val Ile Val Thr Gln Ala Cys Tyr Tyr Glu
130 135 140
Lys Val Lys Asp Leu Gly Val Thr Asn Leu Val Phe Val Asp Ser Pro
145 150 155 160
Pro Glu Gly His Met His Phe Ser Glu Leu Met Ala Asp Asp Asp Asp
165 170 175
Val Ile Thr Gly Asp Glu Ile Lys Ile His Pro Asp Asp Val Val Ala
180 185 190
Leu Pro Tyr Ser Ser Gly Thr Thr Gly Leu Pro Lys Gly Val Met Leu
195 200 205
Thr His Lys Gly Leu Val Thr Ser Ile Ala Gln Gln Val Asp Gly Glu
210 215 220
Asn Pro Asn Leu Tyr Tyr His Ser Glu Asp Val Ile Leu Cys Val Leu
225 230 235 240
Pro Leu Phe His Ile Tyr Ser Leu Asn Ser Val Leu Leu Cys Gly Leu
245 250 255
Arg Ala Lys Ala Ser Ile Leu Leu Met Pro Lys Phe Asp Ile His Ala
260 265 270
Phe Leu Gly Leu Val His Arg His Arg Val Thr Ile Ala Pro Leu Val
275 280 285
Pro Pro Ile Val Leu Ala Ile Ala Lys Ser Pro Asp Leu Asp Lys Tyr
290 295 300
Asp Leu Ser Ser Ile Arg Val Leu Lys Ser Gly Gly Ala Pro Leu Gly
305 310 315 320
Lys Glu Leu Glu Asp Thr Val Arg Ala Lys Phe Pro Gln Ala Lys Leu
325 330 335
Gly Gln Gly Tyr Gly Met Thr Glu Ala Gly Pro Val Leu Thr Met Cys
340 345 350
Leu Ser Phe Ala Lys Val Pro Ile Asp Val Lys Pro Gly Ala Cys Gly
355 360 365
Thr Val Val Arg Asn Ala Glu Met Lys Ile Val Asp Pro Glu Thr Asp
370 375 380
Thr Ser Leu Pro Arg Asn Gln Pro Gly Glu Ile Cys Ile Arg Gly Asp
385 390 395 400
Gln Ile Met Lys Gly Tyr Leu Asn Asp Pro Glu Ala Thr Glu Arg Thr
405 410 415
Ile Asp Lys Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Ile Asp
420 425 430
Asn Asp Asp Glu Leu Phe Ile Val Asp Arg Leu Lys Glu Leu Ile Lys
435 440 445
Tyr Lys Gly Phe Gln Val Ala Pro Ala Glu Leu Glu Ala Leu Ile Leu
450 455 460
Ser His Pro Lys Ile Ser Asp Val Ala Val Val Pro Met Lys Asp Glu
465 470 475 480
Ala Ala Gly Glu Val Pro Val Ala Phe Val Val Arg Ala Asn Gly His
485 490 495
Ile Asp Thr Thr Glu Asp Glu Ile Lys Gln Phe Val Ser Lys Gln Val
500 505 510
Val Phe Tyr Lys Arg Ile Asn Arg Val Phe Phe Ile Asp Ala Ile Pro
515 520 525
Lys Ser Pro Ser Gly Lys Ile Leu Arg Lys Asp Leu Arg Ala Lys Leu
530 535 540
Ala Ala Gly Leu Pro Asn
545 550
<210> 7
<211> 1179
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 7
atggtgagtg tagctgaaat tcgcaaagct caaagggcag aaggccctgc aaacatcttg 60
gccattggca ctgcaaaccc accaaactgt gttgatcaga gtacttatcc tgatttttac 120
tttaagatca caaatagtga gcacaagacc gagcttaagg aaaaatttca gcgcatgtgt 180
gataaatcta tgatcaagaa gcgatatatg tacctaacgg aagagatttt gaaagagaat 240
cctaacattt gcgcttatat ggcaccttct ttggacgcta ggcaagacat ggtggtcgta 300
gaggtgccta gactagggaa ggaagctgcg gtcaaagcta taaaagaatg gggccaacca 360
aagtcgaaga ttacccactt aatcttttgc actactagtg gtgtggacat gcctggcgct 420
gattaccagc ttactaaact cttgggtctt cgcccatatg tgaaaaggta tatgatgtac 480
caacaagggt gctttgcagg tggcacggtg cttcgcttgg ccaaagactt ggcggagaac 540
aacaaaggtg ctcgtgtgct agttgtttgt tctgaagtta ctgcagtcac attccgtggc 600
cctactgata ctcacctaga tagccttgtg ggacaagcat tatttggaga tggagcagct 660
gcagtcattg ttggttctga cccaataccc gaaattgaga agcctatatt tgagttggtt 720
tggactgcac aaacaatagc tccagatagt gaaggagcca ttgatggtca ccttcgtgaa 780
gttgggctca catttcatct tcttaaagat gttcccggga ttgtctcaaa gaacattgat 840
aaagcactga ctgaggcatt ccaaccatta ggcatctctg attacaactc aatcttttgg 900
attgcacacc caggtggacc ggcaattctt gaccaagttg agcaaaagtt agctttgaaa 960
cctgaaaaga tgaaggccac tagggatgtg cttagtgatt atggtaacat gtcaagtgca 1020
tgtgtcctat tcatcttgga tgagatgaga aagaaatccg ctcaaaatgg acttaagacc 1080
actggcgaag ggctcgaatg gggtgtgtta ttcggctttg gacctggact taccatcgaa 1140
actgttgttt tgcacagtgt ggctacatga 1170
<210> 8
<211> 389
<212> PRT
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 8
Met Val Ser Val Ala Glu Ile Arg Lys Ala Gln Arg Ala Glu Gly Pro
1 5 10 15
Ala Asn Ile Leu Ala Ile Gly Thr Ala Asn Pro Pro Asn Cys Val Asp
20 25 30
Gln Ser Thr Tyr Pro Asp Phe Tyr Phe Lys Ile Thr Asn Ser Glu His
35 40 45
Lys Thr Glu Leu Lys Glu Lys Phe Gln Arg Met Cys Asp Lys Ser Met
50 55 60
Ile Lys Lys Arg Tyr Met Tyr Leu Thr Glu Glu Ile Leu Lys Glu Asn
65 70 75 80
Pro Asn Ile Cys Ala Tyr Met Ala Pro Ser Leu Asp Ala Arg Gln Asp
85 90 95
Met Val Val Val Glu Val Pro Arg Leu Gly Lys Glu Ala Ala Val Lys
100 105 110
Ala Ile Lys Glu Trp Gly Gln Pro Lys Ser Lys Ile Thr His Leu Ile
115 120 125
Phe Cys Thr Thr Ser Gly Val Asp Met Pro Gly Ala Asp Tyr Gln Leu
130 135 140
Thr Lys Leu Leu Gly Leu Arg Pro Tyr Val Lys Arg Tyr Met Met Tyr
145 150 155 160
Gln Gln Gly Cys Phe Ala Gly Gly Thr Val Leu Arg Leu Ala Lys Asp
165 170 175
Leu Ala Glu Asn Asn Lys Gly Ala Arg Val Leu Val Val Cys Ser Glu
180 185 190
Val Thr Ala Val Thr Phe Arg Gly Pro Thr Asp Thr His Leu Asp Ser
195 200 205
Leu Val Gly Gln Ala Leu Phe Gly Asp Gly Ala Ala Ala Val Ile Val
210 215 220
Gly Ser Asp Pro Ile Pro Glu Ile Glu Lys Pro Ile Phe Glu Leu Val
225 230 235 240
Trp Thr Ala Gln Thr Ile Ala Pro Asp Ser Glu Gly Ala Ile Asp Gly
245 250 255
His Leu Arg Glu Val Gly Leu Thr Phe His Leu Leu Lys Asp Val Pro
260 265 270
Gly Ile Val Ser Lys Asn Ile Asp Lys Ala Leu Thr Glu Ala Phe Gln
275 280 285
Pro Leu Gly Ile Ser Asp Tyr Asn Ser Ile Phe Trp Ile Ala His Pro
290 295 300
Gly Gly Pro Ala Ile Leu Asp Gln Val Glu Gln Lys Leu Ala Leu Lys
305 310 315 320
Pro Glu Lys Met Lys Ala Thr Arg Asp Val Leu Ser Asp Tyr Gly Asn
325 330 335
Met Ser Ser Ala Cys Val Leu Phe Ile Leu Asp Glu Met Arg Lys Lys
340 345 350
Ser Ala Gln Asn Gly Leu Lys Thr Thr Gly Glu Gly Leu Glu Trp Gly
355 360 365
Val Leu Phe Gly Phe Gly Pro Gly Leu Thr Ile Glu Thr Val Val Leu
370 375 380
His Ser Val Ala Thr
385
<210> 9
<211> 948
<212> DNA
<213> Artificial Sequence
<220>
<223> aritificial sequence
<400> 9
atggctgctg cccctacagt ccctgtaata gttctccctt cctcctctgg acagcggaag 60
atgccggtga tgggactcgg cacggcgccg gaagcaacca gtaaggttac cacaaaggat 120
gctgtccttg aggccatcaa gcagggttac aggcactttg atgctgctgc tgcatatggg 180
gttgagaaat cagtaggaga agccatagca gaagcactta aacttggact acttgcatcc 240
agagatgagg tcttcattac ttccaaactt tgggtcactg acaaccaccc tgaaaccatt 300
gttcctgctc tgaagaaatc tctcaggact cttcaactag aatacttaga cctcattttg 360
atccactggc ccattgctac aaaaccagga gaagttaaat accctattga tgtatcagat 420
attgtggagt ttgacatgaa gggtgtgtgg ggatcattgg aggaatgtca aagacttggt 480
ctcaccaaag ccattggagt cagcaacttc tctatcaaga agcttgaaaa attgctctcc 540
tttgccacca tccctcctgc agtaaatcaa gtggaagtca accttggttg gcaacaagag 600
aaacttagag ctttctgcaa ggaaaagggt attgtcataa ctgctttctc acccctgagg 660
aaaggtgcca gtaggggttc taatttggtg atggacaatg atgtgctgaa agaaattgca 720
gatgctcatg gcaagactat agctcagatt tgtcttcgat ggttatatga acaaggcttg 780
acatttgtgg tgaagagcta tgacaaggag aggatgaatc aaaacttgca gatctttgat 840
tggtcattga ctgaggatga ctacaagaaa ataagtgaaa tctatcaaga gaggctcatc 900
aaaggtccaa ccaagcctct tcttgatgac ctgtgggatg aagaatga 948
<210> 10
<211> 315
<212> PRT
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 10
Met Ala Ala Ala Pro Thr Val Pro Val Ile Val Leu Pro Ser Ser Ser
1 5 10 15
Gly Gln Arg Lys Met Pro Val Met Gly Leu Gly Thr Ala Pro Glu Ala
20 25 30
Thr Ser Lys Val Thr Thr Lys Asp Ala Val Leu Glu Ala Ile Lys Gln
35 40 45
Gly Tyr Arg His Phe Asp Ala Ala Ala Ala Tyr Gly Val Glu Lys Ser
50 55 60
Val Gly Glu Ala Ile Ala Glu Ala Leu Lys Leu Gly Leu Leu Ala Ser
65 70 75 80
Arg Asp Glu Val Phe Ile Thr Ser Lys Leu Trp Val Thr Asp Asn His
85 90 95
Pro Glu Thr Ile Val Pro Ala Leu Lys Lys Ser Leu Arg Thr Leu Gln
100 105 110
Leu Glu Tyr Leu Asp Leu Ile Leu Ile His Trp Pro Ile Ala Thr Lys
115 120 125
Pro Gly Glu Val Lys Tyr Pro Ile Asp Val Ser Asp Ile Val Glu Phe
130 135 140
Asp Met Lys Gly Val Trp Gly Ser Leu Glu Glu Cys Gln Arg Leu Gly
145 150 155 160
Leu Thr Lys Ala Ile Gly Val Ser Asn Phe Ser Ile Lys Lys Leu Glu
165 170 175
Lys Leu Leu Ser Phe Ala Thr Ile Pro Pro Ala Val Asn Gln Val Glu
180 185 190
Val Asn Leu Gly Trp Gln Gln Glu Lys Leu Arg Ala Phe Cys Lys Glu
195 200 205
Lys Gly Ile Val Ile Thr Ala Phe Ser Pro Leu Arg Lys Gly Ala Ser
210 215 220
Arg Gly Ser Asn Leu Val Met Asp Asn Asp Val Leu Lys Glu Ile Ala
225 230 235 240
Asp Ala His Gly Lys Thr Ile Ala Gln Ile Cys Leu Arg Trp Leu Tyr
245 250 255
Glu Gln Gly Leu Thr Phe Val Val Lys Ser Tyr Asp Lys Glu Arg Met
260 265 270
Asn Gln Asn Leu Gln Ile Phe Asp Trp Ser Leu Thr Glu Asp Asp Tyr
275 280 285
Lys Lys Ile Ser Glu Ile Tyr Gln Glu Arg Leu Ile Lys Gly Pro Thr
290 295 300
Lys Pro Leu Leu Asp Asp Leu Trp Asp Glu Glu
305 310 315
<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> aitificial sequence
<400> 11
atgccccatt ctctctccct cttcc 25
<210> 12
<211> 28
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 12
ttaacaaatt ggaagaggtg caccattc 28
<210> 13
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 13
taacatttaa ctccctaccc atttgc 26
<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 14
ccacccctcc attttcccac tac 23
<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 15
cttccaccac ccttacccac tc 22
<210> 16
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 16
gaagcataag cgggcatcat aaaat 25
<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 17
atggtgacag ttgaagagat ccgc 24
<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 18
tcaattagcc tgcaagggaa cactg 25
<210> 19
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 19
ttacaatacc aagagcagct accact 26
<210> 20
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 20
gttcattctt catcccacag gtcat 25
<210> 21
<211> 2127
<212> DNA
<213> Artificial Sequence
<220>
<223> artificial sequence
<400> 21
atggtgagtg tagctgaaat tcgcaaagct caaagggcag aaggccctgc aaacatcttg 60
gccattggca ctgcaaaccc accaaactgt gttgatcaga gtacttatcc tgatttttac 120
tttaagatca caaatagtga gcacaagacc gagcttaagg aaaaatttca gcgcatgtgt 180
gataaatcta tgatcaagaa gcgatatatg tacctaacgg aagagatttt gaaagagaat 240
cctaacattt gcgcttatat ggcaccttct ttggacgcta ggcaagacat ggtggtcgta 300
gaggtgccta gactagggaa ggaagctgcg gtcaaagcta taaaagaatg gggccaacca 360
aagtcgaaga ttacccactt aatcttttgc actactagtg gtgtggacat gcctggcgct 420
gattaccagc ttactaaact cttgggtctt cgcccatatg tgaaaaggta tatgatgtac 480
caacaagggt gctttgcagg tggcacggtg cttcgcttgg ccaaagactt ggcggagaac 540
aacaaaggtg ctcgtgtgct agttgtttgt tctgaagtta ctgcagtcac attccgtggc 600
cctactgata ctcacctaga tagccttgtg ggacaagcat tatttggaga tggagcagct 660
gcagtcattg ttggttctga cccaataccc gaaattgaga agcctatatt tgagttggtt 720
tggactgcac aaacaatagc tccagatagt gaaggagcca ttgatggtca ccttcgtgaa 780
gttgggctca catttcatct tcttaaagat gttcccggga ttgtctcaaa gaacattgat 840
aaagcactga ctgaggcatt ccaaccatta ggcatctctg attacaactc aatcttttgg 900
attgcacacc caggtggacc ggcaattctt gaccaagttg agcaaaagtt agctttgaaa 960
cctgaaaaga tgaaggccac tagggatgtg cttagtgatt atggtaacat gtcaagtgca 1020
tgtgtcctat tcatcttgga tgagatgaga aagaaatccg ctcaaaatgg acttaagacc 1080
actggcgaag ggctcgaatg gggtgtgtta ttcggctttg gacctggact taccatcgaa 1140
actgttgttt tgcacagtgt ggctacaggt ggtggttcta tggctgctgc ccctacagtc 1200
cctgtaatag ttctcccttc ctcctctgga cagcggaaga tgccggtgat gggactcggc 1260
acggcgccgg aagcaaccag taaggttacc acaaaggatg ctgtccttga ggccatcaag 1320
cagggttaca ggcactttga tgctgctgct gcatatgggg ttgagaaatc agtaggagaa 1380
gccatagcag aagcacttaa acttggacta cttgcatcca gagatgaggt cttcattact 1440
tccaaacttt gggtcactga caaccaccct gaaaccattg ttcctgctct gaagaaatct 1500
ctcaggactc ttcaactaga atacttagac ctcattttga tccactggcc cattgctaca 1560
aaaccaggag aagttaaata ccctattgat gtatcagata ttgtggagtt tgacatgaag 1620
ggtgtgtggg gatcattgga ggaatgtcaa agacttggtc tcaccaaagc cattggagtc 1680
agcaacttct ctatcaagaa gcttgaaaaa ttgctctcct ttgccaccat ccctcctgca 1740
gtaaatcaag tggaagtcaa ccttggttgg caacaagaga aacttagagc tttctgcaag 1800
gaaaagggta ttgtcataac tgctttctca cccctgagga aaggtgccag taggggttct 1860
aatttggtga tggacaatga tgtgctgaaa gaaattgcag atgctcatgg caagactata 1920
gctcagattt gtcttcgatg gttatatgaa caaggcttga catttgtggt gaagagctat 1980
gacaaggaga ggatgaatca aaacttgcag atctttgatt ggtcattgac tgaggatgac 2040
tacaagaaaa taagtgaaat ctatcaagag aggctcatca aaggtccaac caagcctctt 2100
cttgatgacc tgtgggatga agaatga 2127

Claims (1)

1.一种生产异甘草素的重组酵母工程菌WM2-2,其特征在于,将重组表达载体pYM1、pYM2和pYM3转入到酵母工程菌WAT11中,
所述重组表达载体pYM1包含苯丙氨酸解氨酶编码基因PAL及肉桂酸4-羟化酶编码基因C4H,所述PAL***双元酵母表达载体pESC-His的启动子GAL1下游,所述C4H***双元酵母表达载体pESC-His的启动子GAL10下游;
所述重组表达载体pYM2包香豆酰-CoA连接酶编码基因4CL、查尔酮合成酶-查尔酮还原酶融合蛋白编码基因CHS::CHR,所述4CL***酵母表达载体pESC-Leu的启动子GAL1下游,所述CHS::CHR***到表达载体pESC-Leu的启动子GAL10下游;
所述重组表达载体pYM3包含查尔酮合成酶-查尔酮还原酶融合蛋白编码基因CHS::CHR,所述CHS::CHR***到表达载体pESC-Trp的启动子GAL10下游,
所述CHS::CHR是经由CHS在3’端通过连接子GGGS编码基因连接到CHR的5’端形成融合基因CHS::CHR;其中,
所述PAL编码SEQ ID NO:2所示氨基酸序列的苯丙氨酸解氨酶,所述C4H编码SEQ IDNO:4所示氨基酸序列的肉桂酸4-羟化酶;
所述4CL编码SEQ ID NO:6所示氨基酸序列的香豆酰-CoA连接酶;
所述CHS::CHR编码由SEQ ID NO:8所示氨基酸序列的查尔酮合成酶和SEQ ID NO:10所示氨基酸序列的查尔酮还原酶组成的融合蛋白,所述查尔酮合成酶和查尔酮还原酶通过连接子GGGS连接。
CN201910392068.1A 2019-05-13 2019-05-13 融合蛋白、其编码基因及在生物合成上的应用 Expired - Fee Related CN110117582B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910392068.1A CN110117582B (zh) 2019-05-13 2019-05-13 融合蛋白、其编码基因及在生物合成上的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910392068.1A CN110117582B (zh) 2019-05-13 2019-05-13 融合蛋白、其编码基因及在生物合成上的应用

Publications (2)

Publication Number Publication Date
CN110117582A CN110117582A (zh) 2019-08-13
CN110117582B true CN110117582B (zh) 2020-12-29

Family

ID=67522210

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910392068.1A Expired - Fee Related CN110117582B (zh) 2019-05-13 2019-05-13 融合蛋白、其编码基因及在生物合成上的应用

Country Status (1)

Country Link
CN (1) CN110117582B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111019852B (zh) * 2019-12-31 2021-11-23 江南大学 一种提高酿酒酵母工程菌株合成葡萄糖二酸效率的方法
CN111748534B (zh) * 2020-08-10 2022-05-10 天津中医药大学 一种SmC4H蛋白及其构建与表达方法
CN115710592B (zh) * 2023-01-09 2023-05-26 成都欧康医药股份有限公司 一种4',5,7-三羟基二氢黄酮的制备工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031622A1 (en) * 2001-10-05 2003-04-17 Agriculture Victoria Services Pty Ltd Manipulation of flavonoid biosynthesis in plants
US7323621B2 (en) * 2002-12-13 2008-01-29 E.I. Du Pont De Nemours And Company Method of decreasing liquiritigenin-derived isoflavones relative to total isoflavones in plants and plants producing reduced ratio of liquiritigenin-derived isoflavones relative to total isoflavones
CN103275996A (zh) * 2013-05-30 2013-09-04 吉林农业大学 大豆查尔酮还原酶基因chr4及应用
CN103333905A (zh) * 2013-05-30 2013-10-02 吉林农业大学 大豆查尔酮还原酶基因chr2及应用
CN103333904A (zh) * 2013-05-30 2013-10-02 吉林农业大学 大豆查尔酮还原酶基因chr3及应用
WO2016071505A1 (en) * 2014-11-07 2016-05-12 Danmarks Tekniske Universitet Microbial production of the flavonoids garbanzol, resokaempferol and fisetin
CN105861545A (zh) * 2016-04-27 2016-08-17 中国烟草总公司郑州烟草研究院 一种提高烟草中类黄酮含量并提升烟草抗旱性的方法及其检测方法
CN107012156A (zh) * 2016-01-28 2017-08-04 刘春生 甘草酸生物合成相关的糖基转移酶基因及其编码产物与应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031622A1 (en) * 2001-10-05 2003-04-17 Agriculture Victoria Services Pty Ltd Manipulation of flavonoid biosynthesis in plants
US7323621B2 (en) * 2002-12-13 2008-01-29 E.I. Du Pont De Nemours And Company Method of decreasing liquiritigenin-derived isoflavones relative to total isoflavones in plants and plants producing reduced ratio of liquiritigenin-derived isoflavones relative to total isoflavones
CN103275996A (zh) * 2013-05-30 2013-09-04 吉林农业大学 大豆查尔酮还原酶基因chr4及应用
CN103333905A (zh) * 2013-05-30 2013-10-02 吉林农业大学 大豆查尔酮还原酶基因chr2及应用
CN103333904A (zh) * 2013-05-30 2013-10-02 吉林农业大学 大豆查尔酮还原酶基因chr3及应用
WO2016071505A1 (en) * 2014-11-07 2016-05-12 Danmarks Tekniske Universitet Microbial production of the flavonoids garbanzol, resokaempferol and fisetin
CN107012156A (zh) * 2016-01-28 2017-08-04 刘春生 甘草酸生物合成相关的糖基转移酶基因及其编码产物与应用
CN105861545A (zh) * 2016-04-27 2016-08-17 中国烟草总公司郑州烟草研究院 一种提高烟草中类黄酮含量并提升烟草抗旱性的方法及其检测方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Assembly of anovel biosynthetic pathway for production of the plant flavonoid fisetin in Escherichia coli;SteenG.Stahlhut等;《Metabolic Engineering》;20151231;第31卷;全文 *
Isobavachalcone: An Overview.;Victor Kuete等;《Chin J Integr Med》;20120731;第18卷(第7期);全文 *
Proteomic insights into synthesis of isoflavonoids in soybean seeds.;Mehran Dastmalchi等;《Proteomics》;20151231;第15卷;全文 *

Also Published As

Publication number Publication date
CN110117582A (zh) 2019-08-13

Similar Documents

Publication Publication Date Title
CN105087408B (zh) 一种生产β-胡萝卜素的酵母菌株及其应用
CN110117582B (zh) 融合蛋白、其编码基因及在生物合成上的应用
CN104357418B (zh) 一种糖基转移酶及其突变体在合成人参皂苷Rh2中的应用
CN109988722B (zh) 一种重组酿酒酵母菌株及其应用和生产酪醇和/或红景天苷的方法
CN107613786A (zh) 产生糖苷的热处理
CN109750071A (zh) 一种生物催化合成莱鲍迪苷m的方法
CN107435049B (zh) 一种生产红景天苷的重组大肠杆菌及构建方法及应用
CN105087739B (zh) 一种新的制备稀有人参皂苷的催化体系及其应用
CN107723252A (zh) 生产巴伦西亚橘烯和诺卡酮的重组解脂耶氏酵母菌及构建方法
CN113416748A (zh) 一种合成***二酚的表达载体、异源表达方法及应用
CN111424020B (zh) 淫羊藿来源半乳糖基转移酶及其在制备金丝桃苷中的应用
CN114207108A (zh) 产生糖基化***素的基因修饰的宿主细胞
CN111154790B (zh) 氧化鲨烯环化酶基因GpOSC1及其编码产物与应用
CN108300726B (zh) α-红没药醇合成质粒及其构建方法与大肠杆菌工程菌株
CN110343678A (zh) 一种珠子参糖基转移酶UGTPjm1基因及在制备人参皂苷Ro上的应用
WO2023208146A1 (zh) 生物合成麦角硫因的方法及载体
CN111235046A (zh) 异源合成α-檀香烯的重组解脂耶氏酵母及其构建方法
CN115927029A (zh) 一种产***萜酚酸的重组酿酒酵母及其构建方法和应用
CN104673814B (zh) 一种来自于阴沟肠杆菌的l‑苏氨酸醛缩酶及其应用
CN112608936B (zh) 调控酵母外源基因表达的启动子,调控方法及其应用
CN114107078A (zh) 一种高产瓦伦烯基因工程菌及其构建方法与应用
CN110004099B (zh) 一种红景天苷的发酵生产方法
CN113817757B (zh) 一种生产樱桃苷的重组酵母工程菌株及应用
CN106701800B (zh) 一种出芽短梗霉聚酮合成酶基因及其应用
KR20240032944A (ko) 람노스가 고도로 특이적인 글리코실트랜스퍼라제 및 이의 응용

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201229